Results 151 to 160 of about 1,166,887 (302)

Platelet-Activating Factor Disrupts the Nasal Epithelial Barrier Independently of the Platelet-Activating Factor Receptor Pathway. [PDF]

Allergy Asthma Immunol Res
Tan J, Han X, Li S, Wang Q, Zhao L, Li Y, Duan S, Zhang L.   +7 more
europepmc   +1 more source

Exposure to diesel exhaust particulates and desert sand dust generates microvesicle particles and platelet-activating factor agonists. [PDF]

Skin Res Technol, 2023
Thyagarajan A, Rapp CM, Schneider L, Lund A, Travers JB, Sahu RP.   +5 more
europepmc   +1 more source

Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival

Advanced Science, EarlyView.
An immunomodulatory hydrogel (iGEL) forms spontaneously upon subcutaneous injection, acting as a tissue‐adhesive depot. It releases anti‐rejection and regenerative agents in response to inflammation, suppressing T‐cell activity, promoting vascular repair, and restoring allograft function without systemic immunosuppression.
Ning Wang, Ruiqi Sun, Yang Fu, Zhonghan Wu, Xinyu Tong, Hong Tang, Wentao Zhao, Zhi Liang, Jintao Zheng, Yanan Guan, Ke Zhou, Penghong Song, Shusen Zheng, Hangxiang Wang, Haiyang Xie   +14 more
wiley   +1 more source

Platelet-Activating Factor Promotes Neutrophil Activation and Platelet-Neutrophil Complex Formation. [PDF]

Scand J Immunol
Wohlgemuth L, Knapp CL, Vidoni L, Hug S, Müller P, Mohamed AOK, Dietz A, Stratmann AEP, Stukan L, Höpfer LM, Thomaß BD, Koller AS, Münnich F, Ruhland M, Huber-Lang M, Messerer DAC.   +15 more
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Structural and molecular dynamics insights into the competitive inhibition of the platelet-activating factor receptor by acyl-PAF. [PDF]

J Biol Chem
Hung SC, Chen CC, Chan HC, Chan ML, Ngui YS, Mei JB, Huang YW, Chaithra VH, Marathe GK, Ke LY.   +9 more
europepmc   +1 more source

The Role of Platelet-Activating Factor and Magnesium in Obstetrics and Gynecology: Is There Crosstalk between Pre-Eclampsia, Clinical Hypertension, and HELLP Syndrome? [PDF]

Biomedicines, 2023
Chawla N, Shah H, Huynh K, Braun A, Wollocko H, Shah NC.   +5 more
europepmc   +1 more source

Lilrb4a Suppression Reprograms Microglia to Mitigate APOE4‐Associated Amyloid Plaques and Cerebral Amyloid Angiopathy in Association With a PPAR‐Linked Pro‐Clearance State

Advanced Science, EarlyView.
Targeting Lilrb4a in Apolipoprotein E4 (APOE4)‐associated Alzheimer's disease (AD) reprograms microglia toward a beneficial, phagocytic state. Genetic deletion or antisense inhibition of Lilrb4a suppresses p‐SHP2/NF‐κB/STAT1 signaling, restores PPAR‐linked lipid and energy metabolism, and reduces amyloid plaque burden and cerebral amyloid angiopathy ...
Changxu Nie, Ruixi Yang, Xiaotong Wang, Ping Jia, Xueqi Zhang, Yaqi Dai, Xue Bai, Sijia Duan, Yufeng Li, Peng Zheng, Xin Tian, Li Jiang, Chao Wang   +12 more
wiley   +1 more source

Platelet-activating factor induces ferroptosis by binding to ATF3 and inhibiting the SLC7A11/GPX4 axis to suppress the progression of endometrial carcinoma. [PDF]

Biol Direct
Pan F, Qiu Y, Huang Z, Zheng Y, Chen Y, Song Y, Chen ZS, Guo L, Wang J, Liu X, Tao Z, Liu Y, Xuan X, Gong K, Shi K.   +14 more
europepmc   +1 more source

Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy? [PDF]

Allergy, 2022
Bilò MB, Corsi A, Martini M, Danieli MG, Alia S, Di Paolo A, Moroncini G, Vignini A.   +7 more
europepmc   +1 more source